Demographic characteristics for the 96 real patient profiles and 702 realistic clinical vignettes
| Real patient profiles (n=96) | Realistic clinical vignettes (n=702) | |
|---|---|---|
| Age | 55.92±15.13 | 55.85±14.21 |
| Female sex | 89 (92.71%) | 647 (92.17%) |
| Disease duration | 8.58±7.25 | 8.46±7.04 |
| Oral dryness | 90 (93.75%) | 641 (91.31%) |
| Ocular dryness | 82 (85.42%) | 599/697 (85.94%) |
| Objectively assessed dryness | 63/63 (100%) | 456/456 (100%) |
| Anti-Ro/SSA antibodies | 82 (86.42%) | 595 (84.76%) |
| Anti-La/SSB antibodies | 56 (58.33%) | 399 (56.84%) |
| Lymphocytic sialadenitis with focus score ≥1 | 70/74 (94.59%) | 490/525 (93.33%) |
| Organ involvement | ||
| Constitutional symptoms | 14 (14.58%) | 76 (10.83%) |
| Lymphadenopathy | 9 (9.38%) | 80 (11.40%) |
| Lymphoma | 8 (8.33%) | 35 (4.99%) |
| Glandular | 27 (28.12%) | 270 (38.46%) |
| Articular | 36 (37.5%) | 396 (56.14%) |
| Cutaneous | 29 (30.21%) | 74 (10.54%) |
| Pulmonary | 22 (22.92%) | 90 (12.82%) |
| Renal | 14 (14.58%) | 37 (5.27%) |
| Muscular | 2 (2.08%) | 22 (3.13%) |
| Peripheral nervous system | 15 (15.62%) | 64 (9.12%) |
| Central nervous system | 7 (7.29%) | 20 (2.85%) |
| Haematological | 25 (26.04%) | 72 (10.26%) |
| Biological markers of B-cell activation | 64 (66.67%) | 268 (38.18%) |
Data are presented as number (%) or mean±SD.